Coeptis Therapeutics, Inc. Stock OTC Markets
Equities
COEP
US19207C1045
Pharmaceuticals
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 11.8M |
---|---|---|---|---|---|
Net income 2024 * | -26M | Net income 2025 * | -35M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.42
x | P/E ratio 2025 * |
-0.37
x | Employees | 6 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 67.46% |
Managers | Title | Age | Since |
---|---|---|---|
David Mehalick
CEO | Chief Executive Officer | 56 | 22-10-27 |
Brian Cogley
DFI | Director of Finance/CFO | 38 | 23-05-16 |
Daniel Yerace
COO | Chief Operating Officer | 41 | 22-10-27 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 62 | 22-10-27 | |
Director/Board Member | 55 | 22-10-27 | |
Christine Sheehy
CMP | Compliance Officer | 57 | 22-10-27 |
1st Jan change | Capi. | |
---|---|---|
+24.17% | 562B | |
-6.46% | 358B | |
+19.65% | 322B | |
+8.18% | 297B | |
+13.45% | 219B | |
+6.04% | 199B | |
-10.51% | 196B | |
-11.76% | 149B | |
-6.45% | 146B |